Op deze website wordt gebruik gemaakt van cookies.

Akkoord

syntax-ii-5-years-esc-1

SYNTAX II is a European multicenter single-arm study investigating the effectiveness of a new generation stent ....

optimal-july-2021-2

dessolve-iii-5-years-6

TALENT is a prospective multicenter randomized post market all-comer trial to assess the safety and effectiveness of the SUPRAFLEX ...

5235dzmx-715x350x1

ECRI provides a structure facilitating trials without the overhead however with the required clinical trial execution expertise.

global-leaders-2021

The GLOBAL LEADERS trial is an Investigator-Sponsored Study (ISS) in which 16,000 “all-comer” patients are enrolled in 131 centers in 18 countries in Europe, Australia, Brazil, Canada & Singapore.
Read more >

A randomized comparison of a rivaroxaban-based strategy with an antiplatelet-based strategy following successful TAVR for the prevention of leaflet thickening and reduced leaflet motion.

Meet the ECRI Scientific Advisory Board

Adrian Banning

Great Britain, Oxford
Oxford University Hospital

Read more
Joost Daemen

Rotterdam, The Netherlands
Erasmus University Medical Center

Read more
Nicolas Van Mieghem

Rotterdam, The Netherlands
Erasmus University Medical Center,

Read more
Luca Testa

Milan, Italy
IRCCS Policlinico San Donato

Read more
José María de la Torre Hernández

Santander, Spain
Hospital Univeristario Marqués de Valdecilla

Read more
Felix Zijlstra

Head Department of Cardiology
Thoraxcenter, Erasmus MC

Read more
Jan Tijssen

Rotterdam, The Netherlands
European Cardiovascular Research Institute

Read more

ECRI 2012-2021